Skip to main content
. 2015 Sep 2;93(3):441–453. doi: 10.4269/ajtmh.14-0625

Table 5.

Seropositivity rates for neutralizing antibody to each DENV type based on priming status (ATP cohort for immunogenicity)

ATP cohort, primed, and unprimed subjects: N = 507
Unprimed subjects Primed Subjects
Antibody Group Timing N % ≥ 1:10 (95% CI) N % ≥ 1:10 (95% CI)
DENV-1 F17 PRE 86 0.0 (0.0–4.2) 91 97.8 (92.3–99.7)
PI(M3) 83 20.5 (12.4–30.8) 88 97.7 (92.0–99.7)
PII(M7) 82 95.1 (88.0–98.7) 87 100 (95.8–100)
F19 PRE 61 0.0 (0.0–5.9) 94 96.8 (91.0–99.3)
PI(M3) 60 26.7 (16.1–39.7) 93 98.9 (94.2–100)
PII(M7) 59 83.1 (71.0–91.6) 90 100 (96.0–100)
DENV-2 F17 PRE 86 0.0 (0.0–4.2) 91 97.8 (92.3–99.7)
PI(M3) 83 26.5 (17.4–37.3) 88 96.6 (90.4–99.3)
PII(M7) 82 89.0 (80.2–94.9) 87 100 (95.8–100)
F19 PRE 61 0 (0.0–5.9) 94 96.8 (91.0–99.3)
PI(M3) 60 43.3 (30.6–56.8) 93 98.9 (94.2–100)
PII(M7) 59 93.2 (83.5–98.1) 90 98.9 (94.0–100)
DENV-3 F17 PRE 86 0.0 (0.0–4.2) 91 96.7 (90.7–99.3)
PI(M3) 83 14.5 (7.7–23.9) 88 96.6 (90.4–99.3)
PII(M7) 82 92.7 (84.8–97.3) 87 100 (95.8–100)
F19 PRE 61 0.0 (0.0–5.9) 94 92.6 (85.3–97.0)
PI(M3) 60 21.7 (12.1–34.2) 93 98.9 (94.2–100)
PII(M7) 59 78.0 (65.3–87.7) 90 98.9 (94.0–100)
DENV-4 F17 PRE 86 0.0 (0.0–4.2) 91 96.7 (90.7–99.3)
PI(M3) 83 37.3 (27.0–48.7) 88 98.9 (93.8–100)
PII(M7) 82 97.6 (91.5–99.7) 87 100 (95.8–100)
F19 PRE 61 0.0 (0.0–5.9) 94 98.9 (94.2–100)
PI(M3) 60 26.7 (16.1–39.7) 93 98.9 (94.2–100)
PII(M7) 59 86.4 (75.0–94.0) 90 98.9 (94.0–100)

ATP = according to protocol; 95% CI = exact 95% confidence interval (lower and upper limits); DENV = dengue virus; N = number of subjects with available results; n/% = number/percentage of subjects with titer > = 1:10; PI(M3) = post-dose 1, Month 3 visit; PII(M7) = post-dose 2, Month 7 visit; PRE = pre-vaccination.